Lucentis and Astigmatism - a phase IV clinical study of FDA data

Summary:

Astigmatism is reported as a side effect among people who take Lucentis (ranibizumab), especially for people who are male, 60+ old, also take Vigamox, and have Choroidal neovascularisation.

The phase IV clinical study analyzes which people have Astigmatism when taking Lucentis. It is created by eHealthMe based on reports of 25,577 people who have side effects when taking Lucentis from the FDA, and is updated regularly.

What is Lucentis?

Lucentis has active ingredients of ranibizumab. It is often used in macular degeneration. eHealthMe is studying from 25,647 Lucentis users. Check the latest studies of Lucentis.

What is Astigmatism?

Astigmatism (refractive error of the eye in which parallel rays of light from an external source do not converge on a single focal point on the retina) is found to be associated with 371 drugs and 414 conditions by eHealthMe. Check the latest studies of Astigmatism.

On Jul, 16, 2026

25,577 people reported to have side effects when taking Lucentis.
Among them, 11 people (0.04%) have Astigmatism.

Among these 11 people:

What is the gender of people who have Astigmatism when taking Lucentis? *

female: 9.09 %
male: 90.91 %

What is the age of people who have Astigmatism when taking Lucentis? *

What are other drugs people take besides Lucentis? *

What are other side effects people have besides Astigmatism? *

Visual Acuity Reduced (reduced clearness of vision): 7 people, 63.64%
Hypermetropia (abnormal condition in which vision for distant objects is better than for near objects): 4 people, 36.36%
Conjunctivitis (pink eye): 4 people, 36.36%
Retinal Oedema (swelling of retina): 4 people, 36.36%
Visual Impairment: 3 people, 27.27%
Visual Field Defect: 3 people, 27.27%
Cataract (clouding of the lens inside the eye): 2 people, 18.18%
Corneal Oedema (corneal swelling): 2 people, 18.18%
Dehydration (dryness resulting from the removal of water): 2 people, 18.18%
Hypoacusis (loss of hearing): 2 people, 18.18%

What are the existing conditions these people have? *

Choroidal Neovascularisation (creation of new blood vessels in vascular layer of eye): 6 people, 54.55%
Retinal Vessel Occlusion (a blockage in one of the small arteries): 2 people, 18.18%
Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 2 people, 18.18%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 2 people, 18.18%
Diabetic Eye Disease: 1 person, 9.09%
Age-Related Macular Degeneration: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Lucentis and have Astigmatism?

- Check whether Astigmatism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lucentis:

Lucentis (25,647 reports)

Astigmatism treatments and more:

Astigmatism (2,086 reports)

Browse all side effects of Lucentis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Astigmatism:

Astigmatism (371 drugs)

Browse all the conditions that are associated with Astigmatism:

Astigmatism (414 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ranibizumab (the active ingredients of Lucentis) and Lucentis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.